DHP107, a novel oral paclitaxel formulation induces less peripheral neuropathic pain and pain-related molecular alteration than intravenous paclitaxel preparation in rat

DHP107, a novel oral paclitaxel formulation induces less peripheral neuropathic pain and pain-related molecular alteration than intravenous paclitaxel preparation in rat

Paclitaxel is used in the treatment of cancer especially in breast, stomach and ovarian cancer. However, peripheral neuropathic pain (PNP) induction is the most common devastating side effect of paclitaxel treatment. The objective of this study was to evaluate the PNP related behavioral changes in r...

Full description

Bibliographic Details
Main Authors: Md. Mahbubur Rahman, Minhee Son, Hyun Kim, In Hyun Lee, Ha young Jeon, Myung Jin Kim, Hansol Kwon, Sung Jin Park, Junhee Jang, Sokho Kim
Format: Article
Language:English
Published: Bangladesh Society for Microbiology, Immunology, and Advanced Biotechnology 2019-08-01
Series:Journal of Advanced Biotechnology and Experimental Therapeutics
Subjects:
paclitaxel
oral formulation
neuropathic pain
Online Access:http://www.ejmanager.com/fulltextpdf.php?mno=38287

Internet

http://www.ejmanager.com/fulltextpdf.php?mno=38287

Similar Items